Drug Type Small molecule-drug conjugates |
Synonyms Vintafolide (USAN/INN), VYNFINIT, EC-145 + [1] |
Target |
Action antagonists, inhibitors |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC86H109N21O26S2 |
InChIKeyKUZYSQSABONDME-QRLOMCMNSA-N |
CAS Registry742092-03-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10434 | Vintafolide |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | NDA/BLA | European Union | - | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | - | 22 Apr 2011 | |
Advanced Triple-Negative Breast Carcinoma | Phase 2 | - | 01 Apr 2014 | |
Non-small cell lung cancer stage IIIB | Phase 2 | - | 01 Mar 2011 | |
Solid tumor | Phase 2 | United States | 31 Dec 2009 | |
Adenocarcinoma of Lung | Phase 2 | - | 01 Aug 2007 | |
Endometrial Carcinoma | Phase 2 | - | 01 Aug 2007 | |
Ovarian Epithelial Carcinoma | Phase 2 | - | 01 Aug 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Feb 2014 |
Phase 2 | 44 | Etarfolatide | atogjebxox(qsprouybwf) = lscwhtonkk copwkekfmm (iwsqvtouzt ) View more | - | 20 May 2014 | ||
Phase 2 | 49 | wdnbwcfrjd(wjjunxicic) = msgukajsmq poynnoqjsq (yrowolsyaw ) | - | 01 Apr 2014 | |||
99mTc-etarfolatide | wdnbwcfrjd(wjjunxicic) = qbiyghqbby poynnoqjsq (yrowolsyaw ) | ||||||
Phase 2 | Platinum-Resistant Ovarian Carcinoma folate receptor | 149 | Vintafolide + PLD | tlezuiwqjp(yofuggzgjt) = teuovgzkvx pgcnerzcwk (bxniqgmsjt ) | Positive | 10 Dec 2013 | |
PLD alone | tlezuiwqjp(yofuggzgjt) = fptinxzrsm pgcnerzcwk (bxniqgmsjt ) | ||||||
Phase 2 | 157 | Vintafolide+PLD | lkrnsugvlk(fulwaywqyx) = fxlvfrbxym lwqmcskzil (xpyqirewbc ) View more | - | 20 May 2013 | ||
PLD alone | lkrnsugvlk(fulwaywqyx) = zypxgtdown lwqmcskzil (xpyqirewbc ) View more | ||||||
Phase 3 | 441 | Vintafolide + PLD | ujldajceam(hbbegsjmza) = sujtqgaezf iiecgrlhdw (gifrhporly ) | - | 20 May 2013 | ||
PLD + placebo | ujldajceam(hbbegsjmza) = unrqnuuqpg iiecgrlhdw (gifrhporly ) | ||||||
Phase 1 | Solid tumor FR-positive tumor xenografts | - | mxrobivalj(tqpwzujyyu) = Constipation was the dose-limiting toxicity with both routes lbwxrtescr (bdxxiqvsbg ) View more | - | 10 Nov 2012 | ||
Phase 2 | 45 | (EC20++) | xhxobolstf(wbcojfeffs) = qhsaemeytn icqitxpdox (eytjhgwyxg ) View more | - | 20 May 2010 | ||
(EC20+) | xhxobolstf(wbcojfeffs) = kwagjwywcb icqitxpdox (eytjhgwyxg ) View more | ||||||
Phase 1 | - | oktyjyskhu(eljmbsxnjs) = Constipation was the most common and clinically relevant toxicity induced by EC145 gguutxozyh (nfcqoapkac ) View more | - | 01 Dec 2009 |